CHK1 activates mitophagy to attenuate cardiac aging via inhibiting AHSA1-ubiquitination Authors: Peng Jing, Liu-Hua Zhou, Shu-Xuan Chen, Jia-Yi Chen, Ling-Feng Gu, Tong-Tong Yang, Si-Bo Wang, Chong Du, Yi-Xi Chen, Qi-Ming Wang, Lian-Sheng Wang, Hao Wang Published: 2026 ABSTRACT With the acceleration of global population aging, the progressive deterioration of cardiac structure and function has become a critical determinant of cardiovascular health, presenting a significant public health challenge. Checkpoint kinase 1 (CHK1), a key cell cycle checkpoint protein, plays an essential role in various biological processes by mediating signaling cascades. While CHK1 has been shown to be important for heart regeneration, its role in the aging process of the heart remains unclear. In this study, we investigated the alterations in CHK1 expression in aging hearts and elucidated the underlying regulatory mechanisms. In both in vivo and in vitro models, CHK1 expression was significantly downregulated during aging. To assess its functional role, we generated cardiomyocyte-specific CHK1 overexpression and knockout mice and compared their cardiac performance. We found that CHK1 overexpression alleviated age-associated cardiac dysfunction, while CHK1 knockout worsened cardiac function in aged mice. Furthermore, CHK1 overexpression significantly attenuated doxorubicin (DOX)-induced acutely senescence in adult mouse cardiomyocytes (AMCMs) and human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs). Mechanistic studies revealed that CHK1 overexpression delayed cardiac aging by activating heat shock protein 90 (HSP90)-mediated mitophagy. Immunoprecipitation and mass spectrometry (IP-MS) analyses demonstrated that CHK1 directly interacts with the activator of HSP90 ATPase homolog 1 (AHSA1), thereby suppressing TRIM8-mediated ubiquitination and degradation, facilitating AHSA1-HSP90 complex formation, and enhancing HSP90 ATPase activity. Overall, our results suggest that CHK1 overexpression activates mitophagy via the AHSA1-HSP90 pathway to mitigate cardiac aging. This study highlights the critical role of CHK1 in cardiac aging and proposes a potential therapeutic strategy for aging-associated cardiomyopathy and heart failure. Introduction Cardiovascular diseases (CVD) continue to represent the primary cause of morbidity and mortality worldwide [1]. According to the 2024 World Health Organization (WHO) report, CVD accounts for nearly 20 million deaths annually, constituting approximately 32% of all global fatalities, and presents a significant challenge to healthcare systems and socioeconomic sustainability, particularly influenced by population aging [2]. Age is firmly established as an independent risk factor for CVD, significantly impacting disease onset, progression, and clinical outcomes [3]. Throughout the aging process, the cardiovascular system undergoes cumulative structural remodeling and functional impairment, leading to an increased susceptibility to cardiovascular events and worsened clinical outcomes [4]. Nevertheless, the molecular and cellular mechanisms through which aging drives cardiovascular pathology, as well as the development of effective therapeutic strategies, remain poorly defined, highlighting the critical necessity for further investigation. Aging, a progressive process unfolding over time, is associated with a decline in functional reserves, perturbation of systemic homeostasis, and an increased risk of age-associated pathological alterations [5]. Even without manifest cardiovascular disease, aging induces significant structural and functional modifications in the heart, typified by ventricular hypertrophy, myocardial interstitial fibrosis, and impaired systolic and diastolic performance [6]. Cellular senescence constitutes a pivotal pathogenic mechanism underpinning the decline in cardiac function associated with aging [7]. Characterized by an irreversible cessation of the cell cycle, cellular senescence is accompanied by a range of canonical phenotypic features, including cardiomyocyte hypertrophy, increased expression of cyclin-dependent kinase inhibitors such as p21 and p16INK4A, augmented secretion of senescence-associated secretory phenotype (SASP) (such as IL-1β, IL-6 and TNF-α), and mitochondrial dysfunction [[8], [9], [10]]. These alterations collectively disrupt cardiomyocyte homeostasis, thereby exacerbating cardiac structural remodeling and functional deterioration. While the detrimental effects of aging on cardiac structure and function have been extensively documented, the underlying molecular mechanisms, particularly the coordinated interactions of cellular and molecular networks that drive functional deterioration, remain poorly delineated. In recent years, significant research efforts have been dedicated to elucidating the molecular mechanisms governing cardiomyocyte senescence and identifying potential therapeutic and interventional approaches for age-associated CVD. Accumulating evidence highlights the critical significance of mitochondrial quality control in orchestrating the pathophysiological remodeling and functional decline of the aging heart [11]. Given the heart's continuous engagement in electrical activity and contraction-relaxation cycles, it experiences a substantial ATP demand, underscoring the essential role of mitochondrial functional integrity in maintaining cardiac homeostasis [12]. In adults, each contraction utilizes roughly 200 mg of ATP, culminating in an estimated total daily ATP consumption of approximately 30 kg. This highlights a dense mitochondrial network in cardiomyocytes, which accounts for 30-35% of the cell volume [13]. Senescent cardiomyocytes commonly exhibit mitochondrial structural abnormalities and functional deterioration, characterized by impaired oxidative phosphorylation, decreased ATP production, excessive ROS generation, mitochondrial DNA (mtDNA) mutations, and disrupted mitochondrial homeostasis, where mitophagy assumes a pivotal role in safeguarding mitochondrial integrity and sustaining cellular functions [14,15]. Mitochondrial damage induced by senescence exacerbates oxidative stress and drives cardiomyocyte senescence, whereas augmenting mitophagy to eliminate dysfunctional mitochondria and preserve mitochondrial function can markedly delay this process [16]. These findings highlight the pivotal role of mitochondrial dysfunction and its regulatory imbalance in cardiac aging, yet the precise molecular mechanisms and potential therapeutic avenues remain largely undefined. Checkpoint kinase 1 (CHK1), a canonical cell cycle checkpoint protein, plays a central role in regulating biological processes, encompassing cell proliferation [17] and apoptosis [18]. Its primary function involves sensing genomic damage and coordinating a precisely regulated series of repair responses to uphold genomic integrity, thereby ensuring the accurate progression of the cell cycle [[19], [20], [21]]. Our previous studies have demonstrated that CHK1 overexpression enhances cardiomyocyte proliferation after myocardial infarction in adult mice, improving cardiac function and promoting heart regeneration [17]. However, the involvement and underlying mechanisms of CHK1 in cardiac aging remain largely unexplored. In this study, we observed a significant reduction in CHK1 expression across diverse in vivo and in vitro models of senescence. CHK1 overexpression effectively attenuated doxorubicin (DOX)-induced acutely senescence in adult mouse cardiomyocytes (AMCMs) in vitro. In vivo, cardiomyocyte-specific CHK1 overexpression notably delayed cardiac aging, whereas cardiomyocyte-specific CHK1 knockout had the opposite effects. RNA-seq analysis indicated that CHK1 activates heat shock protein 90 (HSP90)-mediated mitophagy, thereby retarding cardiac aging. Additionally, through immunoprecipitation coupled with mass spectrometry (IP/MS) and co-immunoprecipitation (Co-IP) analyses, we demonstrated that CHK1 directly binds to and stabilizes the activator of HSP90 ATPase homolog 1 (AHSA1) by suppressing TRIM8-mediated ubiquitination and proteasomal degradation, thereby promoting AHSA1-HSP90 complex formation and enhancing HSP90 ATPase activity. In summary, these results underscore the pivotal role of CHK1 in cardiac aging and elucidate its molecular mechanisms, providing a foundational basis for targeted interventions aimed at delaying or potentially reversing cardiac aging. Materials and methods Animals Male wild-type (WT) C57BL/6J mice (1, 2, 12, and 24 months old) were purchased from the university's Animal Core Facility and maintained under specific pathogen-free conditions. Transgenic lines with cardiomyocyte-specific transgenic mice overexpressing CHK1 (CHK1-TG) or heterozygous cardiomyocyte-specific CHK1 knockout mice (CHK1-cKO) were generated by GemPharmatech Inc. CHK1-TG mice were established by targeted insertion of the CHK1 sequence into the H11 locus, with cardiomyocyte-specific expression achieved through Myh6-Cre–mediated removal of a floxed stop cassette. For CHK1-cKO mice, Myh6-Cre animals were bred with CHK1flox/+ mice to obtain heterozygous cardiomyocyte-specific knockout offspring. Genotypes were verified by PCR using primer sets listed in the Supplemental Table 1. In the study, mice were sacrificed via cervical dislocation after anesthesia for cardiac tissue collection. Anesthesia was induced in mice by intraperitoneal injection of 1.2% Avertin, which was chosen for its superior hemodynamic profile, eliciting less bradycardia and exerting fewer effects on cardiac loading and ventricular function than the xylazine-ketamine combination [22,23]. All procedures involving animals were approved by the Animal Care and Use Committee of Nanjing Medical University (No. 1601038, Nanjing, China) and conducted in accordance with the NIH Guide for the Care and Use of Laboratory Animals (NIH Publication No. 86-23, revised 2011). Study protocols for animal studies Male CHK1fl/fl and CHK1-cKO mice were longitudinally followed from 1 to 24 months of age. These mice were sequentially evaluated for myocardial structure and function as detailed below. Animals were euthanized at 1 and 24 months of age, and cardiac tissues were harvested for histological and molecular analyses. Male wild-type (WT) and CHK1-TG mice were longitudinally followed from 1 to 24 months of age. These mice were sequentially evaluated for myocardial structure and function as detailed below. Animals were euthanized at 1 and 24 months of age, and cardiac tissues were harvested for histological and molecular analyses. Echocardiography All mice were anesthetized with inhaled isoflurane (0.5-1.0%). Transthoracic echocardiography was performed using a high-resolution imaging system (Vevo 2100 or Vevo 3100, VisualSonics) equipped with a 40-MHz linear array transducer specifically designed for small-animal imaging. Left ventricular ejection fraction (LVEF), left ventricular fractional shortening (LVFS), and left ventricular internal diameter (LVID) were quantified from M-mode recordings. For each mouse, measurements were obtained in triplicate, and mean values were used for statistical analysis. All echocardiographic evaluations were conducted by certified technicians at the Experimental Animal Center of Nanjing Medical University, with the operators blinded to group allocation. Cell culture and intervention As previously reported, we isolated and cultured adult mouse cardiomyocytes (AMCMs) [24]. In brief, hearts were harvested from adult WT mice at 2 months of age. and immediately subjected to langendorff perfusion via aortic cannulation using calcium-free buffer. Enzymatic dissociation was then carried out with 1 mg/mL type II collagenase (pH 7.4) to facilitate myocardial digestion. Upon completion of digestion, hearts were detached from the perfusion apparatus, atrial tissue was removed, and ventricular myocardium was gently minced in enzyme-containing solution. The liberated cells were obtained through gentle mechanical dispersion and low-speed centrifugation at 20g. The cell pellet was briefly exposed to stop solution for 1 min, followed by gravity sedimentation at room temperature. Calcium was then gradually titrated to a final concentration of 1 mM to improve cell viability and eliminate compromised cells. The enriched cardiomyocyte fraction was subsequently resuspended in M199 medium supplemented with BSA, 2,3-BDM, and penicillin–streptomycin, plated onto Matrigel-coated culture surfaces, and incubated at 37 °C in a humidified atmosphere with 5% CO2 for downstream analyses. As previously reported [25], human induced pluripotent stem cells (hiPSCs) were commercially obtained from Nanjing Elp Regenerative Medicine Technology Co., Ltd and subsequently differentiated into cardiomyocytes in vitro. Cardiomyocyte differentiation was performed using a stepwise small-molecule induction protocol. Undifferentiated hiPSCs at approximately 90% confluence were exposed to differentiation medium 1 (#1; RPMI 1640 supplemented with B27 minus insulin and 2-phospho-l-ascorbic acid trisodium salt) containing 6 μM CHIR-99021 for days 0-1. On day 2, induction conditions were terminated by replacement with #1 medium alone, followed by inhibitory modulation using #1 medium supplemented with 5 μM IWR-1 during days 3-4. From day 5 to day 8, cultures were maintained in #1 medium and subsequently transitioned to maturation medium 2 (#2; RPMI 1640 supplemented with B27 and 2-phospho-l-ascorbic acid trisodium salt), with medium refreshed every other day. At day 30 post-differentiation, hiPSC-derived cardiomyocytes (hiPSC-CMs) were collected for downstream analyses. HEK293T cells were obtained from the China Center for Type Culture Collection and cultured in DMEM supplemented with 10% FBS and 1% penicillin/streptomycin. Transfection with CHK1 and AHSA1 plasmids was carried out using Lipofectamine 3000 (Thermo Fisher Scientific, USA) following the manufacturer's instructions. For CHK1 modulation in vitro, cells were transduced with Ad5:cTNT-CHK1 or Ad5:cTNT-CHK1i at a multiplicity of infection (MOI) of 50 for 48 h. Control cells were transduced with Ad5:cTNT-vector or Ad5:cTNT-vectori. Transduced cardiomyocytes were subsequently used for downstream experiments. To induce aging model in vitro, cells were cultured in modified eagle medium (MEM) containing 5% calf serum (CS) for 24 h, followed by treatment with Doxorubicin (DOX) in the same medium for specified durations at 37 °C [26,27]. Construction of recombinant adenovirus (Ad5), adeno-associated virus 9 (AAV9) and plasmids Recombinant adenoviruses (Ad5-CHK1, Ad5-CHK1i, Ad5-PINK1i, and corresponding controls) and AAV9 vectors (AAV9-AHSA1, AAV9-AHSA1i, AAV9-PINK1i, and controls) were purchased from Genechem (Shanghai, China). Tandem mCherry-EGFP-LC3 adenovirus was obtained from HanBio (Shanghai, China). Plasmids encoding Flag-CHK1 (full length and truncations) and HA-AHSA1 were purchased from Genechem. Detailed information is provided in the Supplemental materials. RNA-sequencing analysis Total RNA was isolated from WT (24 months old) and CHK1-TG (24 months old) C57BL/6J mice heart using TRIzol reagent, following the manufacturer's protocol. RNA integrity, concentration, and purity were evaluated using a NanoDrop 2000 spectrophotometer. RNA-seq libraries were constructed with the VAHTS Universal V5 RNA-seq Library Prep Kit according to the manufacturer's instructions. Libraries were sequenced on the Illumina NovaSeq 6000 platform to generate 150 bp paired-end reads. Raw sequencing data were processed with fastp for adapter trimming and quality filtering. Clean reads were subsequently aligned to the reference genome using HISAT2. Differential expression analysis was performed using DESeq2, and genes with P value < 0.05 and |fold change| > 2 were considered significantly differentially expressed. Gene Ontology (GO) and Gene Set Enrichment Analysis (GSEA) analyses were performed using the “ClusterProfiler” R package (version 4.2.2) in R (version 4.1.1). Immunoprecipitation coupled with mass spectrometry (IP/MS) CHK1 and AHSA1 immunoprecipitates were resolved by SDS-PAGE and subjected to silver staining (P0017S, Beyotime, China). Distinct bands were excised and digested as previously described [24]. Briefly, gel slices were destained, reduced with DTT, alkylated with iodoacetamide, and digested with trypsin overnight at 37 °C. The resulting peptides were extracted, desalted, dried, and reconstituted for analysis. LC-MS/MS analysis was performed by Wuhan Genecreate Biological Engineering Co., Ltd using a Orbitrap Fusion Lumos coupled to an Easy-nLC 1200 system. Peptides were separated on a C18 reverse-phase column using a 60 min gradient. For data analysis, raw MS files were processed using MaxQuant and searched against the UniProt Mus musculus database. The mass tolerance for both precursor and fragment ions was set to 20 ppm. Trypsin was specified as the digestion enzyme with a maximum of 2 missed cleavages. Protein identification required a False Discovery Rate (FDR) of <1% at both peptide and protein levels. Only proteins identified with at least 1 unique peptide were considered for further analysis. Immunofluorescent staining Paraffin-embedded heart sections (4 μm) were deparaffinized and subjected to antigen retrieval, then gradually cooled to room temperature. Cells were fixed with 4% paraformaldehyde for 15 min, followed by blocking and permeabilization in PBS containing 5% BSA and 0.1% Triton X-100 for 2 h at room temperature. Samples were incubated with primary antibodies overnight at 4 °C. After washing three times with PBST, secondary antibodies were applied for 2 h at room temperature. Following another three PBST washes, nuclei were stained with Hoechst 33342. Fluorescent images were acquired using a Zeiss confocal microscope (Oberkochen, Germany). The details of the antibodies used were provided in the Supplemental Tables 2 and 3 For ROS detection, Dihydroethidium (DHE) staining was measured as previously described [28]. Briefly, fresh myocardial tissue was snap-frozen, sectioned at 4 μm, and incubated with the DHE probe (S0063, Beyotime, China) for 30 min at 37 °C. Nuclei were subsequently counterstained with Hoechst 33342 for 20 min at room temperature. As for cell, DHE staining was performed directly without 4% PFA and 10% goat serum treatment. Fluorescent images were captured for analysis using a Zeiss confocal microscope (Oberkochen, Germany). Transmission electron microscopy (TEM) analysis Fresh myocardial tissue was dissected into approximately 1 mm3 sections and initially fixed in 2.5% glutaraldehyde for 2 h at room temperature, followed by storage at 4 °C. Samples were dehydrated through a graded ethanol series, embedded in epoxy resin, and ultrathin sections (80 nm) were prepared and mounted on copper grids. Imaging was performed using a FEI Tecnai G2 transmission electron microscope (Thermo Fisher Scientific, USA). Quantitative real time-polymerase chain reaction (qRT-PCR) Total RNA was extracted from cells or myocardial tissues using TRIzol reagent (Thermo Fisher Scientific, Waltham, USA) according to the manufacturer's instructions. RNA quality and concentration were evaluated prior to reverse transcription with HiScript III RT SuperMix (R323-01, Vazyme Biotech, Nanjing, China) to synthesize cDNA. qRT-PCR was performed using SYBR Green (Q131-02, Vazyme Biotech) with 18S or β-actin as the control gene. Relative gene expression was calculated using the ΔΔCt method. Primer sequences were listed in the Supplemental Table 1. Western blot Cells or myocardial tissues were lysed in lysis buffer (P0013B, Beyotime, China) supplemented with 1% protease inhibitor cocktail (P1005, Beyotime, China) and 1% phosphatase inhibitor (P1045, Beyotime, China). Protein extracts were separated by SDS-PAGE and transferred onto PVDF membranes. Membranes were blocked with 5% non-fat milk for 2 h at room temperature, followed by overnight incubation at 4 °C with primary antibodies. After three 10-min washes with TBST, membranes were incubated with HRP-conjugated secondary antibodies for 2 h at room temperature and washed three additional times. Protein signals were detected via chemiluminescence, and band intensities were quantified using ImageJ software. The details of the antibodies used were provided in the Supplemental Tables 2 and 3 Statistical analysis Statistical analyses were performed using GraphPad Prism 8.0. Data were presented as mean ± standard error of the mean (SEM) and were confirmed to follow a normal distribution. Comparisons between two groups were conducted using unpaired Student's t-test, while multiple group comparisons were analyzed by one-way or two-way ANOVA followed by Tukey's post hoc test. A P-value <0.05 was considered statistically significant. Supplementary materials and methods Please refer to the “Supplementary Methods” section in the Supplementary material online for detailed methods and materials regarding Masson's Trichrome staining, Hematoxylin and eosin (H&E) staining, Measurement of oxygen consumption rate (OCR), ATP Measurement, Construction of recombinant adenovirus (Ad5), adeno-associated virus 9 (AAV9) and plasmids, Mitophagy analysis, Autophagic flux assay, Terminal deoxynucleotidyl transferase-mediated dUTP Nick End Labeling (Tunel) assay, Wheat germ agglutinin (WGA) staining, Co-immunoprecipitation assay, Measurement of 8-hydroxy-2′-deoxyguanosine (8-OHdG), malondialdehyde (MDA), 4-hydroxynonenal (4-HNE), and superoxide dismutase (SOD) and Immunoprecipitation and HSP90 ATPase assay. Results CHK1 attenuates cardiomyocyte senescence To explore the relationship between CHK1 expression and cardiac aging, myocardial samples were collected from mice at different postnatal stages, revealing a decrease in CHK1 expression levels with advancing age (Fig. 1A–C). Primary cardiomyocytes were subsequently isolated from adult and aged mice, and CHK1 protein expression was significantly reduced in aged cardiomyocytes compared with adult cardiomyocytes (Supplemental Fig. 1A–B). Meanwhile, adult mouse cardiomyocytes (AMCMs) were isolated and treated with doxorubicin (DOX) to establish an in vitro acute senescence model, which resulted in a significant reduction in CHK1 expression (Fig. 1D–E). Notably, decreased CHK1 levels were consistently observed across multiple DOX-induced premature senescence models, including H9c2, AC16, and hiPSC-derived cardiomyocytes, suggesting a potential role for CHK1 in the regulation of cardiomyocyte senescence (Fig. 1F–G, Supplemental Fig. 1C–F). Collectively, these findings indicate that CHK1 expression progressively declines during cardiac aging.Fig. 1CHK1 expression declines with cardiac aging and its overexpression alleviates DOX-induced acutely cardiomyocyte senescence. A, Western Blot analysis and quantification of CHK1 protein expression in mice hearts (n = 6). B, qRT-PCR analysis and quantification of CHK1 mRNA expression in mice hearts (n = 6). C, Representative immunofluorescent images of CHK1 expression from mice hearts. cTNT (green), CHK1 (red), Hoechst (blue). Scale bar = 20 μm. D, Western Blot analysis and quantification of CHK1 protein expression in AMCMs upon DOX treatment (n = 6). E, qRT-PCR analysis and quantification of CHK1 mRNA expression in AMCMs upon DOX treatment (n = 6). F, Western Blot analysis and quantification of CHK1 protein expression in hiPSC-CMs upon DOX treatment (n = 6). G, qRT-PCR analysis and quantification of CHK1 mRNA expression in hiPSC-CMs upon DOX treatment (n = 6). H, Western Blot analysis and quantification of IL-1β and IL-6 proteins expression in AMCMs transfected with Ad5: cTNT-vector or Ad5: cTNT-CHK1 after DOX treatment (n = 6). I, Western Blot analysis and quantification of p21 and p16INK4A proteins expression in AMCMs transfected with Ad5: cTNT-vector or Ad5: cTNT-CHK1 after DOX treatment (n = 6). J, qRT-PCR analysis and quantification of ANP and BNP mRNA expression in AMCMs transfected with Ad5: cTNT-vector or Ad5: cTNT-CHK1 after DOX treatment (n = 6). K, Representative immunofluorescent images and quantification of cardiomyocyte size in AMCMs transfected with Ad5: cTNT-vector or Ad5: cTNT-CHK1 after DOX treatment (n = 6). cTNT (green), Hoechst (blue). Scale bar = 10 μm. A-B. Statistical analyses were performed by one-way ANOVA followed by Tukey multiple comparisons. D-K. Statistical analyses were performed by unpaired Student t-test. CHK1 expression declines with cardiac aging and its overexpression alleviates DOX-induced acutely cardiomyocyte senescence. A, Western Blot analysis and quantification of CHK1 protein expression in mice hearts (n = 6). B, qRT-PCR analysis and quantification of CHK1 mRNA expression in mice hearts (n = 6). C, Representative immunofluorescent images of CHK1 expression from mice hearts. cTNT (green), CHK1 (red), Hoechst (blue). Scale bar = 20 μm. D, Western Blot analysis and quantification of CHK1 protein expression in AMCMs upon DOX treatment (n = 6). E, qRT-PCR analysis and quantification of CHK1 mRNA expression in AMCMs upon DOX treatment (n = 6). F, Western Blot analysis and quantification of CHK1 protein expression in hiPSC-CMs upon DOX treatment (n = 6). G, qRT-PCR analysis and quantification of CHK1 mRNA expression in hiPSC-CMs upon DOX treatment (n = 6). H, Western Blot analysis and quantification of IL-1β and IL-6 proteins expression in AMCMs transfected with Ad5: cTNT-vector or Ad5: cTNT-CHK1 after DOX treatment (n = 6). I, Western Blot analysis and quantification of p21 and p16INK4A proteins expression in AMCMs transfected with Ad5: cTNT-vector or Ad5: cTNT-CHK1 after DOX treatment (n = 6). J, qRT-PCR analysis and quantification of ANP and BNP mRNA expression in AMCMs transfected with Ad5: cTNT-vector or Ad5: cTNT-CHK1 after DOX treatment (n = 6). K, Representative immunofluorescent images and quantification of cardiomyocyte size in AMCMs transfected with Ad5: cTNT-vector or Ad5: cTNT-CHK1 after DOX treatment (n = 6). cTNT (green), Hoechst (blue). Scale bar = 10 μm. A-B. Statistical analyses were performed by one-way ANOVA followed by Tukey multiple comparisons. D-K. Statistical analyses were performed by unpaired Student t-test. To investigate the function of CHK1 in the acute senescence model, we initially verified that adenoviral-mediated CHK1 overexpression (Ad5:cTNT-CHK1) efficiently upregulated CHK1 levels in AMCMs (Supplemental Fig. 2A–B). qRT-PCR analysis of SASP factors (IL-1β, IL-6, TGF-α, and CCL2) in DOX-induced acutely senescent AMCMs revealed that CHK1 overexpression markedly suppressed SASP mRNA levels, particularly showing marked reductions in IL-1β and IL-6 (Supplemental Fig. 2C). Concurrently, Western blot analysis confirmed that CHK1 overexpression also diminished the protein levels of IL-1β and IL-6 in DOX-induced acutely senescent AMCMs (Fig. 1H). Furthermore, CHK1 overexpression markedly reduced both mRNA and protein levels of senescence-associated markers (p21 and p16INK4A) in DOX-induced acutely senescent AMCMs (Fig. 1I, Supplemental Fig. 2D). Additionally, immunofluorescent staining for cTNT demonstrated that CHK1 overexpression reduced cardiomyocytes hypertrophy in DOX-induced acutely senescent AMCMs, accompanied with decreased mRNA expression levels of ANP and BNP (Fig. 1J–K). These in vitro functional data suggest that CHK1 may attenuate cardiomyocyte senescence in DOX-induced acutely senescent AMCMs. CHK1 overexpression alleviates cardiac aging in mice, whereas CHK1 knockout exacerbates the aging process To further investigate the effects of CHK1 on cardiac aging, cardiomyocyte-specific CHK1 overexpression (CHK1-TG) mice were generated (Supplemental Fig. 3A and Supplemental Fig. 3C–D). No significant differences were observed between 1-month-old groups at baseline (Fig. 2A–D). In contrast, 24-month-old CHK1-TG mice exhibited a marked attenuation of age-associated cardiac hypertrophy compared with 24-month-old WT mice, as evidenced by reduced HW/BW and HW/TL ratios, decreased cardiomyocyte cross-sectional area, and downregulated ANP and BNP expression (Fig. 2A–D). Histologically, 24-month-old CHK1-TG mice displayed preserved cardiac fibers with more compactly organized relative to 24-month-old WT mice, whereas no discernible differences were observed at 1 month of age (Fig. 2E). Consistently, echocardiographic assessment and Masson's trichrome staining revealed significantly improved cardiac function and reduced fibrotic scar size in 24-month-old CHK1-TG mice, with no comparable changes detected in 1-month-old mice (Fig. 2F–G). In addition, CHK1-TG markedly suppressed SASP factors (IL-1β and IL-6) and reduced p21 and p16INK4A expression in 24-month-old cardiac tissue, but not in 1-month-old mice (Fig. 2H–K). Taken together, these findings indicate that CHK1 overexpression protects against cardiac aging by mitigating structural, functional, and molecular deterioration.Fig. 2CHK1 overexpression protects against cardiac aging in mice. A, Heart weight to body weight (HW/BW) ratio in 1- and 24-month-old WT and CHK1-TG mice (n = 12). B, Heart weight/Tibia length (HW/TL) ratio in 1- and 24-month-old WT and CHK1-TG mice (n = 12). C, qRT-PCR analysis and quantification of ANP and BNP mRNA expression in cardiac tissue from 1- and 24-month-old WT and CHK1-TG mice (n = 6). D, WGA immunofluorescence staining and quantification analysis of cardiomyocyte size in cardiac tissue from 1- and 24-month-old WT and CHK1-TG mice (n = 6). WGA (red), Hoechst (blue). Scale bar = 10 μm. E, Representative images of H&E staining in cardiac tissue from 1- and 24-month-old WT and CHK1-TG mice. Scale bar = 200 μm. F, Representative Masson's trichrome staining images and quantification of fibrotic area in cardiac tissue from 1- and 24-month-old WT and CHK1-TG mice (n = 6). Scale bar = 100 μm. G, Representative echocardiographic images and quantification of left ventricular ejection fraction (EF), fractional shortening (FS), left ventricular internal dimension at end-diastole (LVID; d) and left ventricular internal dimension at end-systole (LVID; s) in 1- and 24-month-old WT and CHK1-TG mice (1-month-old WT and CHK1-TG mice: n = 6, 24-month-old WT and CHK1-TG mice: n = 8). H, qRT-PCR analysis and quantification of IL-1β and IL-6 mRNA expression in cardiac tissue from 1- and 24-month-old WT and CHK1-TG mice (n = 6). I, Western Blot analysis and quantification of IL-1β and IL-6 proteins expression in cardiac tissue from 1- and 24-month-old WT and CHK1-TG mice (n = 6). J, qRT-PCR analysis and quantification of p21 and p16INK4A mRNA expression in cardiac tissue from 1- and 24-month-old WT and CHK1-TG mice (n = 6). K, Western Blot analysis and quantification of p21 and p16INK4A proteins expression in cardiac tissue from 1- and 24-month-old WT and CHK1-TG mice (n = 6). A-D. and F–K. Statistical analyses were performed by two-way ANOVA followed by Tukey multiple comparisons. CHK1 overexpression protects against cardiac aging in mice. A, Heart weight to body weight (HW/BW) ratio in 1- and 24-month-old WT and CHK1-TG mice (n = 12). B, Heart weight/Tibia length (HW/TL) ratio in 1- and 24-month-old WT and CHK1-TG mice (n = 12). C, qRT-PCR analysis and quantification of ANP and BNP mRNA expression in cardiac tissue from 1- and 24-month-old WT and CHK1-TG mice (n = 6). D, WGA immunofluorescence staining and quantification analysis of cardiomyocyte size in cardiac tissue from 1- and 24-month-old WT and CHK1-TG mice (n = 6). WGA (red), Hoechst (blue). Scale bar = 10 μm. E, Representative images of H&E staining in cardiac tissue from 1- and 24-month-old WT and CHK1-TG mice. Scale bar = 200 μm. F, Representative Masson's trichrome staining images and quantification of fibrotic area in cardiac tissue from 1- and 24-month-old WT and CHK1-TG mice (n = 6). Scale bar = 100 μm. G, Representative echocardiographic images and quantification of left ventricular ejection fraction (EF), fractional shortening (FS), left ventricular internal dimension at end-diastole (LVID; d) and left ventricular internal dimension at end-systole (LVID; s) in 1- and 24-month-old WT and CHK1-TG mice (1-month-old WT and CHK1-TG mice: n = 6, 24-month-old WT and CHK1-TG mice: n = 8). H, qRT-PCR analysis and quantification of IL-1β and IL-6 mRNA expression in cardiac tissue from 1- and 24-month-old WT and CHK1-TG mice (n = 6). I, Western Blot analysis and quantification of IL-1β and IL-6 proteins expression in cardiac tissue from 1- and 24-month-old WT and CHK1-TG mice (n = 6). J, qRT-PCR analysis and quantification of p21 and p16INK4A mRNA expression in cardiac tissue from 1- and 24-month-old WT and CHK1-TG mice (n = 6). K, Western Blot analysis and quantification of p21 and p16INK4A proteins expression in cardiac tissue from 1- and 24-month-old WT and CHK1-TG mice (n = 6). A-D. and F–K. Statistical analyses were performed by two-way ANOVA followed by Tukey multiple comparisons. Furthermore, cardiomyocyte-specific CHK1 knockout (CHK1-cKO) mice were generated to further explore the role of CHK1 in cardiac aging, which was confirmed by markedly reduced CHK1 expression in cardiac tissue (Supplemental Fig. 3B and Supplemental Fig. 3E–F). At 1 month of age, cardiac parameters were comparable across groups (Supplemental Fig. 4A–D). In aged mice, CHK1-cKO mice exhibited pronounced cardiac hypertrophy relative to CHK1fl/fl mice, as evidenced by increased HW/BW and HW/TL ratios, enlarged cardiomyocyte cross-sectional area, and elevated ANP and BNP expression (Supplemental Fig. 4A–D). Histological analysis revealed pronounced myocardial disorganization in aged CHK1-cKO hearts compared with 24-month-old CHK1fl/fl mice, with no discernible abnormalities observed in 1-month-old mice (Supplemental Fig. 4E). In parallel, echocardiography and Masson's trichrome staining demonstrated impaired cardiac function and increased fibrotic scar size in 24-month-old CHK1-cKO mice (Supplemental Fig. 4F–G). Meanwhile, compared with 24-month-old CHK1fl/fl mice, 24-month-old CHK1-cKO mice showed enhanced SASP activation, as indicated by increased IL-1β and IL-6 levels, along with upregulated p21 and p16INK4A expression in aged myocardium, with no detectable changes in 1-month-old mice (Supplemental Fig. 4H–K). Collectively, these results demonstrate that CHK1 knockout accelerates cardiac aging, identifying CHK1 as a key regulator of this process. CHK1 alleviates oxidative stress through PINK1/Parkin-mediated mitophagy in aged mice To uncover the downstream molecular mechanisms implicated in CHK1-mediated regulation of cardiac aging, we conducted RNA-seq analysis on hearts from 24-month-old CHK1-TG and WT mice. A total of 191 differentially expressed genes were identified, comprising 144 upregulated and 47 downregulated genes (Supplemental Fig. 5A). Gene set enrichment analysis (GSEA) revealed that CHK1 overexpression positively regulates adaptive responses to oxidative stress (Fig. 3A), a process closely associated with cardiomyocyte senescence [6,9]. These results prompted the hypothesis that CHK1 may delay cardiac aging in aged mice by maintaining redox homeostasis. Accordingly, we comprehensively profiled oxidative stress by assessing ROS production (DHE), oxidative DNA damage (γH2AX and 8-OHdG), lipid peroxidation (MDA and 4-HNE), and antioxidant capacity (SOD). At 1 month of age, oxidative stress-related parameters were indistinguishable among WT, CHK1-TG, CHK1fl/fl and CHK1-cKO mice, consistent with a comparable basal redox equilibrium (Fig. 3B–G, Supplemental Fig. 6A–F). In contrast, CHK1-TG mice displayed a broadly attenuated oxidative stress profile at 24 months of age relative to 24-month-old WT mice, as reflected by reduced ROS production, decreased γH2AX and 8-OHdG levels, and lower accumulation of lipid peroxidation products, including MDA and 4-HNE, accompanied by preserved SOD activity (Fig. 3B–G). Conversely, 24-month-old CHK1-cKO mice showed a pronounced exacerbation of oxidative stress, characterized by increased ROS production, exacerbated oxidative DNA damage, increased lipid peroxidation, and impaired antioxidant capacity (Supplemental Fig. 6A–F). These results demonstrate a critical role of CHK1 in maintaining redox homeostasis in the aged myocardium. Cardiomyocyte apoptosis was evaluated by Tunel staining to investigate whether CHK1 regulates age-associated cardiomyocyte death. We found that minimal Tunel-positive cardiomyocytes were detected in 1-month-old mice across WT, CHK1-TG, CHK1fl/fl and CHK1-cKO groups (Supplemental Figs. 6G and 7A). However, in aged hearts, CHK1-TG mice exhibited a reduced number of Tunel-positive cardiomyocytes compared with WT mice, whereas CHK1-cKO hearts exhibited the opposite trend with increased apoptosis (Supplemental Figs. 6G and 7A). Collectively, these results suggest that CHK1 preserves cardiomyocyte survival during cardiac aging.Fig. 3CHK1 suppresses oxidative stress via PINK1/Parkin-dependent mitophagy in aged mice. A, GSEA analysis of gene clusters in regulation of oxidative stress response. B, Representative immunofluorescent images and quantification of relative fluorescence intensity of DHE staining in cardiac tissue from 1- and 24-month-old WT and CHK1-TG mice (n = 6). DHE (orange), Hoechst (blue). Scale bar = 50 μm. C, Representative immunofluorescent images and quantification of relative fluorescence intensity of γH2AX staining in cardiac tissue from 1- and 24-month-old WT and CHK1-TG mice (n = 6). cTNT (red), γH2AX (green), Hoechst (blue). Scale bar = 20 μm. D, Quantification of 8-OHdG levels in cardiac tissue from 1- and 24-month-old WT and CHK1-TG mice (n = 6) E, Quantification of MDA levels in cardiac tissue from 1- and 24-month-old WT and CHK1-TG mice (n = 6). F, Quantification of 4-HNE intensity in cardiac tissue from 1- and 24-month-old WT and CHK1-TG mice (n = 6). G, Quantification of SOD activity in cardiac tissue from 1- and 24-month-old WT and CHK1-TG mice (n = 6). H, GO term analysis of differentially expressed genes in cardiac tissue from 24-month-old WT and CHK1-TG mice. I, Western Blot analysis and quantification of proteins (PINK1, Parkin, p62 and LC3-Ⅱ) expression in cardiac tissue from 24-month-old WT and CHK1-TG mice (n = 6). J, Representative images and quantification of colocalization of PINK1 and Tomm20 in cardiac tissue from 24-month-old WT and CHK1-TG mice (n = 6). PINK1 (red), Tomm20 (green), Hoechst (blue). Scale bar = 5 μm. K, Representative images and quantification of colocalization of LC3 and Tomm20 in AMCMs transfected with Ad5: cTNT-vector or Ad5: cTNT-CHK1 after DOX treatment (n = 6). LC3 (red), Tomm20 (green), Hoechst (blue)Scale bar = 10 μm. L, Representative TEM images and quantification of mitophagosome and mitochondria morphology in cardiac tissue from 24-month-old WT and CHK1-TG mice (n = 6). Scale bar = 1 μm. M, Representative images and quantification of colocalization of Mito-Tracer and Lyso-Tracer in AMCMs transfected with Ad5: cTNT-vector or Ad5: cTNT-CHK1 after DOX treatment (n = 6). Lyso-Tracer (red), Mito-Tracer (green), Hoechst (blue). Scale bar = 10 μm. N, Cellular oxygen consumption rate (OCR) in AMCMs transfected with Ad5: cTNT-vector or Ad5: cTNT-CHK1 following DOX treatment was measured to assess mitochondrial bioenergetics (n = 6). O, ATP contents in AMCMs transfected with Ad5: cTNT-vector or Ad5: cTNT-CHK1 following DOX treatment (n = 6). B-G. Statistical analyses were performed by two-way ANOVA followed by Tukey multiple comparisons. I–O. Statistical analyses were performed by unpaired Student t-test. CHK1 suppresses oxidative stress via PINK1/Parkin-dependent mitophagy in aged mice. A, GSEA analysis of gene clusters in regulation of oxidative stress response. B, Representative immunofluorescent images and quantification of relative fluorescence intensity of DHE staining in cardiac tissue from 1- and 24-month-old WT and CHK1-TG mice (n = 6). DHE (orange), Hoechst (blue). Scale bar = 50 μm. C, Representative immunofluorescent images and quantification of relative fluorescence intensity of γH2AX staining in cardiac tissue from 1- and 24-month-old WT and CHK1-TG mice (n = 6). cTNT (red), γH2AX (green), Hoechst (blue). Scale bar = 20 μm. D, Quantification of 8-OHdG levels in cardiac tissue from 1- and 24-month-old WT and CHK1-TG mice (n = 6) E, Quantification of MDA levels in cardiac tissue from 1- and 24-month-old WT and CHK1-TG mice (n = 6). F, Quantification of 4-HNE intensity in cardiac tissue from 1- and 24-month-old WT and CHK1-TG mice (n = 6). G, Quantification of SOD activity in cardiac tissue from 1- and 24-month-old WT and CHK1-TG mice (n = 6). H, GO term analysis of differentially expressed genes in cardiac tissue from 24-month-old WT and CHK1-TG mice. I, Western Blot analysis and quantification of proteins (PINK1, Parkin, p62 and LC3-Ⅱ) expression in cardiac tissue from 24-month-old WT and CHK1-TG mice (n = 6). J, Representative images and quantification of colocalization of PINK1 and Tomm20 in cardiac tissue from 24-month-old WT and CHK1-TG mice (n = 6). PINK1 (red), Tomm20 (green), Hoechst (blue). Scale bar = 5 μm. K, Representative images and quantification of colocalization of LC3 and Tomm20 in AMCMs transfected with Ad5: cTNT-vector or Ad5: cTNT-CHK1 after DOX treatment (n = 6). LC3 (red), Tomm20 (green), Hoechst (blue)Scale bar = 10 μm. L, Representative TEM images and quantification of mitophagosome and mitochondria morphology in cardiac tissue from 24-month-old WT and CHK1-TG mice (n = 6). Scale bar = 1 μm. M, Representative images and quantification of colocalization of Mito-Tracer and Lyso-Tracer in AMCMs transfected with Ad5: cTNT-vector or Ad5: cTNT-CHK1 after DOX treatment (n = 6). Lyso-Tracer (red), Mito-Tracer (green), Hoechst (blue). Scale bar = 10 μm. N, Cellular oxygen consumption rate (OCR) in AMCMs transfected with Ad5: cTNT-vector or Ad5: cTNT-CHK1 following DOX treatment was measured to assess mitochondrial bioenergetics (n = 6). O, ATP contents in AMCMs transfected with Ad5: cTNT-vector or Ad5: cTNT-CHK1 following DOX treatment (n = 6). B-G. Statistical analyses were performed by two-way ANOVA followed by Tukey multiple comparisons. I–O. Statistical analyses were performed by unpaired Student t-test. To delve deeper into the mechanisms underlying CHK1's enhancement of oxidative stress homeostasis, we conducted Gene Ontology (GO) enrichment analysis, which revealed that differentially expressed genes were mainly enriched in pathways associated with the positive regulation of mitophagy (Fig. 3H). Given the pivotal role of the PINK1/Parkin signaling pathway in mediating mitophagy and maintaining mitochondrial quality and cellular homeostasis [29], we hypothesize that CHK1 may improve oxidative stress homeostasis by regulating PINK1/Parkin-mediated mitophagy. Subsequent Western blot analysis of PINK1, Parkin, p62, and LC3-II revealed robust activation of the PINK1/Parkin-mediated mitophagy pathway in CHK1-TG mice (Fig. 3I). To further investigate the role of CHK1 in regulating PINK1/Parkin-mediated mitophagy in vivo, immunofluorescence staining of PINK1 and Tomm20 was performed in aged hearts. Compared with WT mice, CHK1-TG mice exhibited increased mitochondrial PINK1 colocalization (Fig. 3J). In parallel, mitophagy was assessed in DOX-induced acutely senescent AMCMs by LC3 and Tomm20 co-staining. Consistently, CHK1 overexpression enhanced LC3 colocalization with mitochondria (Fig. 3K). Moreover, autophagic flux was assessed in DOX-induced acutely senescent AMCMs using Ad-mCherry-EGFP-LC3 transfection. Quantification of the autophagosome-to-autolysosome ratio revealed that CHK1 overexpression restored the impaired autophagic flux in senescent cardiomyocytes (Supplemental Fig. 8A). Furthermore, LC3 levels were analyzed by Western blot under pharmacological modulation of autophagy at distinct stages, including early-stage inhibition with 3-MA and late-stage lysosomal blockade with chloroquine (CQ). Results showed that 3-MA treatment significantly decreased LC3-II levels in DOX-induced acutely senescent AMCMs, and this reduction was markedly attenuated by CHK1 overexpression (Supplemental Fig. 8B), indicating that CHK1 promotes autophagosome formation. CQ treatment resulted in a more pronounced accumulation of LC3-II in the CHK1 overexpression group (Supplemental Fig. 8C), suggesting CHK1 enhances autophagic flux rather than impairing autophagosome formation or lysosomal degradation. Transmission electron microscopy (TEM) analysis further revealed a significant increase in autophagosome numbers and preserved mitochondrial structure in CHK1-TG hearts compared to WT mice (Fig. 3L). We next investigated whether CHK1 regulates mitochondrial clearance in aged cardiomyocytes, with particular emphasis on mitophagy. Lyso-tracker and Mito-tracker staining demonstrated reduced colocalization of mitochondria and lysosomes in aged cardiomyocytes, which was markedly restored by CHK1 overexpression (Fig. 3M). Additionally, CHK1 overexpression was found to improve mitochondrial bioenergetics, as evidenced by OCR measurements and ATP contents in DOX-induced acutely senescent AMCMs (Fig. 3N–O). These results indicate that CHK1 improves redox homeostasis by activating PINK1/Parkin-dependent mitophagy in aged cardiomyocytes. PINK1 knockdown diminishes the protective effects of CHK1 overexpression on mitophagy and cardiac aging in aged cardiomyocytes To further validate this conclusion, we conducted a combined experiment in which WT-24 M and CHK1-TG-24 M mice were intravenously injected with cardiomyocyte-specific PINK1 knockdown virus or control virus (Fig. 4A). Immunofluorescence staining demonstrated that PINK1 knockdown attenuated PINK1 colocalization with Tomm20, while CHK1 overexpression markedly improved this effect (Fig. 4B). Subsequently, Western blot analysis demonstrated that PINK1 knockdown impaired mitophagy, as evidenced by decreased LC3-II levels and increased p62 accumulation in mitochondrial-enriched fractions of aged myocardium, an effect that was partially reversed by CHK1 overexpression (Fig. 4C). Consistently, we further confirmed that PINK1 knockdown attenuated mitophagic activity, as indicated by decreased colocalization of LC3 with Tomm20 and reduced colocalization of mitochondria with lysosomes, and that these effects were largely reversed by CHK1 overexpression (Supplemental Fig. 9A–B). In addition, Immunofluorescence analysis further revealed that PINK1 knockdown significantly increased ROS levels and exacerbated DNA damage in aged mice, whereas CHK1 overexpression reversed these effects (Fig. 4D–E). Furthermore, immunofluorescence analysis showed that PINK1 knockdown markedly promoted apoptosis in aged cardiomyocytes, an effect that was significantly attenuated by CHK1 overexpression (Supplemental Fig. 10A). To assess whether inhibition of mitophagy could reverse the protective effects of CHK1 on delaying cardiac aging, we performed Western blot analyses. We found that PINK1 knockdown significantly increased protein levels of IL-1β, IL-6, p21, and p16INK4A in the myocardium of aged mice, while CHK1 overexpression attenuated these elevations (Fig. 4F–G). Consistently, WGA staining revealed pronounced cardiomyocyte hypertrophy after PINK1 knockdown, which was partially reversed by CHK1 overexpression (Fig. 4H). Moreover, echocardiographic and Masson's staining analyses demonstrated that PINK1 knockdown exacerbated cardiac dysfunction and increased fibrotic scar size, effects counteracted by CHK1 overexpression (Fig. 4I–J). These results suggest that CHK1 overexpression may partially mitigate the impairment of mitophagy and cardiac aging induced by PINK1 knockdown.Fig. 4PINK1 knockdown diminishes the protective effects of CHK1 on mitophagy and cardiac aging in aging mice. A, Schematic diagram. 24-month-old WT and CHK1-TG mice were injected with adeno-associated virus 9 (AAV9) encoding either cTNT-vectori or cTNT-PINK1i. B, Representative images and quantification of colocalization of PINK1 and Tomm20 in cardiac tissue from each group (n = 6). PINK1 (red), Tomm20 (green), Hoechst (blue). Scale bar = 5 μm. C, Western Blot analysis and quantification of proteins (p62 and LC3-Ⅱ) expression in cardiac tissue from each group (n = 6). D, Representative immunofluorescent images and quantification of relative fluorescence intensity of DHE staining in cardiac tissue from each group (n = 6). DHE (orange), Hoechst (blue). Scale bar = 50 μm. E, Representative immunofluorescent images and quantification of relative fluorescence intensity of γH2AX staining in cardiac tissue from each group (n = 6). cTNT (red), γH2AX (green), Hoechst (blue). Scale bar = 20 μm. F, Western Blot analysis and quantification of IL-1β and IL-6 proteins expression in cardiac tissue from each group (n = 6). G, Western Blot analysis and quantification of p21 and p16INK4A proteins expression in cardiac tissue from each group (n = 6). H, WGA immunofluorescence staining and quantification analysis of cardiomyocyte size in cardiac tissue from each group (n = 6). WGA (red), Hoechst (blue). Scale bar = 10 μm. I, Quantification of left ventricular EF, FS, LVID; d and LVID; s in each group (n = 6). J, Representative Masson's trichrome staining images and quantification of fibrotic area in cardiac tissue from each group (n = 6). Scale bar = 100 μm. B-J. Statistical analyses were performed by one-way ANOVA followed by Tukey multiple comparisons. PINK1 knockdown diminishes the protective effects of CHK1 on mitophagy and cardiac aging in aging mice. A, Schematic diagram. 24-month-old WT and CHK1-TG mice were injected with adeno-associated virus 9 (AAV9) encoding either cTNT-vectori or cTNT-PINK1i. B, Representative images and quantification of colocalization of PINK1 and Tomm20 in cardiac tissue from each group (n = 6). PINK1 (red), Tomm20 (green), Hoechst (blue). Scale bar = 5 μm. C, Western Blot analysis and quantification of proteins (p62 and LC3-Ⅱ) expression in cardiac tissue from each group (n = 6). D, Representative immunofluorescent images and quantification of relative fluorescence intensity of DHE staining in cardiac tissue from each group (n = 6). DHE (orange), Hoechst (blue). Scale bar = 50 μm. E, Representative immunofluorescent images and quantification of relative fluorescence intensity of γH2AX staining in cardiac tissue from each group (n = 6). cTNT (red), γH2AX (green), Hoechst (blue). Scale bar = 20 μm. F, Western Blot analysis and quantification of IL-1β and IL-6 proteins expression in cardiac tissue from each group (n = 6). G, Western Blot analysis and quantification of p21 and p16INK4A proteins expression in cardiac tissue from each group (n = 6). H, WGA immunofluorescence staining and quantification analysis of cardiomyocyte size in cardiac tissue from each group (n = 6). WGA (red), Hoechst (blue). Scale bar = 10 μm. I, Quantification of left ventricular EF, FS, LVID; d and LVID; s in each group (n = 6). J, Representative Masson's trichrome staining images and quantification of fibrotic area in cardiac tissue from each group (n = 6). Scale bar = 100 μm. B-J. Statistical analyses were performed by one-way ANOVA followed by Tukey multiple comparisons. CHK1 promotes PINK1/Parkin-mediated mitophagy through activating HSP90 ATPase activation in aged cardiomyocytes To explore the molecular intermediates through which CHK1 regulates PINK1/Parkin-mediated mitophagy, we performed additional GO analysis, revealing that differentially expressed genes were predominantly associated with HSP90 protein binding (Fig. 3H). As a highly conserved molecular chaperone, HSP90 maintains protein homeostasis through interactions with diverse client proteins, influencing essential processes such as apoptosis, autophagy, and ferroptosis [[30], [31], [32]]. Therefore, we further investigated the role of HSP90 in this process. Subsequent qRT-PCR and Western blot analyses revealed that neither CHK1 overexpression nor knockout affected HSP90 expression at the mRNA or protein level (Supplemental Fig. 11A–D). Since HSP90 primarily exerts its function through ATPase activity [33], we then assessed HSP90 ATPase activity and observed that CHK1-TG mice significantly increased HSP90 ATPase activity compared to WT mice, whereas CHK1-cKO mice showed markedly reduced activity (Supplemental Fig. 11E–F). Previous studies have shown that HSP90 overexpression enhances mitophagy and alleviates heat stress in Wenchang chicken hepatocytes, whereas HSP90 knockdown suppresses mitophagy and reduces cisplatin sensitivity in human osteosarcoma cells [33]. Collectively, these findings suggest that HSP90 may serve as a downstream mediator linking CHK1 to mitophagy activation. To further determine whether HSP90 directly regulates mitophagy under senescent conditions, we pharmacologically activated HSP90 ATPase activity with tamoxifen (an HSP90 ATPase activator) in DOX-induced acutely senescent AMCMs [34,35]. Activation of HSP90 ATPase activity markedly enhanced mitophagy, as evidenced by increased LC3-II levels, reduced p62 accumulation, and improved colocalization of LC3 with Tomm20 and mitochondria with lysosomes (Supplemental Fig. 12A–D). These data indicate that HSP90 can activate mitophagy in senescent cardiomyocytes. To further delineate the functional relationship between HSP90 and the PINK1/Parkin pathway, combined HSP90 activation and PINK1 knockdown experiments were performed. Activation of HSP90 ATPase activity partially rescued mitophagy impairment induced by PINK1 knockdown in DOX-induced acutely senescent AMCMs (Supplemental Fig. 13A–D), suggesting that HSP90 critically regulates PINK1/Parkin-mediated mitophagy in senescent cardiomyocytes. Based on the above results, we postulated that CHK1 may regulate PINK1/Parkin-mediated mitophagy by activating HSP90 ATPase activity. Next, we performed functional rescue experiments to further delineate the role of HSP90 ATPase activity in CHK1-mediated attenuation of cardiomyocyte senescence via activation of PINK1/Parkin-mediated mitophagy. In DOX-induced acutely senescent AMCMs, cells were transfected with Ad5:cTNT-CHK1 and subsequently treated with the HSP90 ATPase inhibitor 17-AAG or DMSO [36]. As shown, 17-AAG significantly diminished the CHK1 overexpression-induced increase in HSP90 ATPase activity (Supplemental Fig. 14A). We then assessed mitochondrial function. The results demonstrated that 17-AAG markedly blunted CHK1-induced activation of PINK1/Parkin-mediated mitophagy (Supplemental Fig. 14B–D). Collectively, these findings suggest that CHK1 maintains PINK1/Parkin-dependent mitophagy in aged cardiomyocytes through activating HSP90 ATPase activity. CHK1Δ1-265 interacts with AHSA1 To further investigate the molecular mediators through which CHK1 promotes HSP90-dependent mitophagy, we performed immunoprecipitation combined with mass spectrometry (IP-MS) to identify CHK1-interacting proteins in the myocardium of 24-month-old CHK1-TG mice (Fig. 5A). A total of 20 proteins were identified, among which activator of HSP90 ATPase homolog 1 (AHSA1), a known potent activator of the HSP90 ATPase domain, was revealed [37]. Previous studies have demonstrated that TL-2-8 inhibits the AHSA1-HSP90 complex formation, leading to impaired HSP90 chaperone activity and lysosomal-associated membrane protein 2 (LAMP2) processing, ultimately suppressing mitophagy [38]. Hence, AHSA1 was identified as a potential downstream target of CHK1 (Fig. 5B–C). Co-IP assays validated the interaction between CHK1 and AHSA1 in DOX-treated acutely senescent AMCMs transfected with Ad5:cTNT-CHK1 in vitro (Fig. 5D). Meanwhile, in vivo analyses further validated the interaction between CHK1 and AHSA1 (Fig. 5E). To further characterize the CHK1-AHSA1 interaction, molecular docking analysis using the ClusPro server identified amino acids 1-265 of CHK1 as the putative domain mediating this interaction (Fig. 5F). To determine the CHK1 domain responsible for binding AHSA1, Flag-tagged CHK1 truncation constructs (Δ265, Δ390) and full-length CHK1 were generated based on UniProt data [39] (Fig. 5G). These constructs were transfected into HEK293T cells, and subsequent Co-IP assays revealed that all constructs, including CHK1Δ265, CHK1Δ390, and full-length CHK1, interacted with HA-AHSA1 (Fig. 5H). These results confirm that CHK1Δ1–265 can interact with AHSA1, consistent with the molecular docking analysis findings.Fig. 5The Δ1-265 domain of CHK1 binds to AHSA1. A, Schematic illustration of the experimental strategy used to identify downstream targets of CHK1. B, IP/MS identified AHSA1 as a downstream target of CHK1. C, Identification of AHSA1 through mass spectrometry analysis. D, Representative Western blot images following Co-IP using anti-CHK1 antibody or anti-AHSA1 antibody in AMCMs transfected with Ad5: cTNT-CHK1 following DOX treatment. E, Representative Western blot images following Co-IP using anti-CHK1 antibody or anti-AHSA1 antibody in cardiac tissue from 24-month-old CHK1-TG mice. F, Molecular docking analysis illustrating the interaction between CHK1 and AHSA1 domains, with CHK1 shown in yellow and AHSA1 shown in purple. G, Construction of plasmids encoding CHK1 full-length (CHK1-FL, amino acids 1-476), CHK1Δ390 (amino acids 1-390), and CHK1Δ265 (amino acids 1-265). H, Representative Western blot analysis of CHK1 and AHSA1 following Co-IP in 293T cells co-transfected with Flag-CHK1 constructs (FL, Δ390, Δ265) and HA-AHSA1. The Δ1-265 domain of CHK1 binds to AHSA1. A, Schematic illustration of the experimental strategy used to identify downstream targets of CHK1. B, IP/MS identified AHSA1 as a downstream target of CHK1. C, Identification of AHSA1 through mass spectrometry analysis. D, Representative Western blot images following Co-IP using anti-CHK1 antibody or anti-AHSA1 antibody in AMCMs transfected with Ad5: cTNT-CHK1 following DOX treatment. E, Representative Western blot images following Co-IP using anti-CHK1 antibody or anti-AHSA1 antibody in cardiac tissue from 24-month-old CHK1-TG mice. F, Molecular docking analysis illustrating the interaction between CHK1 and AHSA1 domains, with CHK1 shown in yellow and AHSA1 shown in purple. G, Construction of plasmids encoding CHK1 full-length (CHK1-FL, amino acids 1-476), CHK1Δ390 (amino acids 1-390), and CHK1Δ265 (amino acids 1-265). H, Representative Western blot analysis of CHK1 and AHSA1 following Co-IP in 293T cells co-transfected with Flag-CHK1 constructs (FL, Δ390, Δ265) and HA-AHSA1. CHK1 suppresses TRIM8-mediated ubiquitination and degradation of AHSA1, thereby promoting its interaction with HSP90 To further delineate their functional interplay, we investigated the mechanistic basis underlying CHK1's modulation of AHSA1. qRT-PCR analysis showed that CHK1 expression did not alter AHSA1 mRNA level (Supplemental Fig. 15A–B), while Western blot analysis revealed that CHK1 overexpression markedly increased AHSA1 protein level, with CHK1 knockout producing the opposite effect (Supplemental Fig. 15C–D), collectively suggesting post-transcriptional regulation. To understand how CHK1 influences AHSA1 protein levels, Western blot analysis revealed that CHK1 overexpression markedly delayed AHSA1 degradation in DOX-induced acutely senescent AMCMs treated with cycloheximide (CHX), whereas CHK1 knockdown accelerated degradation (Fig. 6A–B). To assess whether CHK1 regulates AHSA1 stability through the proteasome pathway, Western blot analysis revealed that MG132 treatment rescued the AHSA1 reduction induced by CHK1 knockdown, indicating that CHK1 stabilizes AHSA1 by inhibiting its proteasome-mediated degradation (Fig. 6C–D). Furthermore, assessment of AHSA1 ubiquitination by Co-IP following CHK1 overexpression or knockout demonstrated that CHK1 overexpression markedly decreased AHSA1 ubiquitination, whereas CHK1 knockout increased it (Fig. 6E–F). These findings collectively indicate that CHK1 directly interacts with AHSA1 and inhibits its degradation via a ubiquitin-proteasome-dependent mechanism.Fig. 6CHK1 inhibits the ubiquitin-proteasome mediated degradation of AHSA1, thereby promoting its interaction with HSP90. A, Western Blot analysis and quantification of AHSA1 protein expression in AMCMs transfected with Ad5: cTNT-vector or Ad5: cTNT-CHK1 and treated with CHX (200 μM) for 0, 4, 8, 12h following DOX treatment (n = 6). B, Western Blot analysis and quantification of AHSA1 protein expression in AMCMs transfected with Ad5: cTNT-vectori or Ad5: cTNT-CHK1i and treated with CHX (200 μM) for 0, 4, 8, 12h following DOX treatment (n = 6). C, Western Blot analysis and quantification of AHSA1 protein expression in AMCMs transfected with Ad5: cTNT-vector or Ad5: cTNT-CHK1 and treated with MG132 (20 μM) following DOX treatment (n = 6). D, Western Blot analysis and quantification of AHSA1 protein expression in AMCMs transfected with Ad5: cTNT-vectori or Ad5: cTNT-CHK1i and treated with MG132 (20 μM) following DOX treatment (n = 6). E, Co-IP assay and Western blot analysis of the ubiquitination level of AHSA1 in cardiac tissue from 24-month-old WT and CHK1-TG mice. F, Co-IP assay and Western blot analysis of the ubiquitination level of AHSA1 in cardiac tissue from 24-month-old CHK1fl/fl and CHK1-cKO mice. G, Co-IP assay and Western blot analysis of the interaction between AHSA1 and TRIM8 in cardiac tissue from 24-month-old WT and CHK1-TG mice. H, Co-IP assay and Western blot analysis of the interaction between AHSA1 and TRIM8 in cardiac tissue from 24-month-old CHK1fl/fl and CHK1-cKO mice. I, Co-IP assay and Western blot analysis of the interaction between AHSA1 and HSP90 in cardiac tissue from 24-month-old WT and CHK1-TG mice. J, Co-IP assay and Western blot analysis of the interaction between AHSA1 and HSP90 in cardiac tissue from 24-month-old CHK1fl/fl and CHK1-cKO mice. A-B. Statistical analyses were performed by unpaired Student t-test. C-D. Statistical analyses were performed by one-way ANOVA followed by Tukey multiple comparisons. CHK1 inhibits the ubiquitin-proteasome mediated degradation of AHSA1, thereby promoting its interaction with HSP90. A, Western Blot analysis and quantification of AHSA1 protein expression in AMCMs transfected with Ad5: cTNT-vector or Ad5: cTNT-CHK1 and treated with CHX (200 μM) for 0, 4, 8, 12h following DOX treatment (n = 6). B, Western Blot analysis and quantification of AHSA1 protein expression in AMCMs transfected with Ad5: cTNT-vectori or Ad5: cTNT-CHK1i and treated with CHX (200 μM) for 0, 4, 8, 12h following DOX treatment (n = 6). C, Western Blot analysis and quantification of AHSA1 protein expression in AMCMs transfected with Ad5: cTNT-vector or Ad5: cTNT-CHK1 and treated with MG132 (20 μM) following DOX treatment (n = 6). D, Western Blot analysis and quantification of AHSA1 protein expression in AMCMs transfected with Ad5: cTNT-vectori or Ad5: cTNT-CHK1i and treated with MG132 (20 μM) following DOX treatment (n = 6). E, Co-IP assay and Western blot analysis of the ubiquitination level of AHSA1 in cardiac tissue from 24-month-old WT and CHK1-TG mice. F, Co-IP assay and Western blot analysis of the ubiquitination level of AHSA1 in cardiac tissue from 24-month-old CHK1fl/fl and CHK1-cKO mice. G, Co-IP assay and Western blot analysis of the interaction between AHSA1 and TRIM8 in cardiac tissue from 24-month-old WT and CHK1-TG mice. H, Co-IP assay and Western blot analysis of the interaction between AHSA1 and TRIM8 in cardiac tissue from 24-month-old CHK1fl/fl and CHK1-cKO mice. I, Co-IP assay and Western blot analysis of the interaction between AHSA1 and HSP90 in cardiac tissue from 24-month-old WT and CHK1-TG mice. J, Co-IP assay and Western blot analysis of the interaction between AHSA1 and HSP90 in cardiac tissue from 24-month-old CHK1fl/fl and CHK1-cKO mice. A-B. Statistical analyses were performed by unpaired Student t-test. C-D. Statistical analyses were performed by one-way ANOVA followed by Tukey multiple comparisons. To identify the E3 ligase mediating CHK1-regulated ubiquitination of AHSA1, we performed IP-MS analysis using cardiac tissues from CHK1-cKO mice. A total of 84 candidate proteins were identified, among which TRIM8 emerged as the only E3 ligase (Supplemental Fig. 16A). TRIM8, a member of the tripartite motif family, is known to regulate substrate stability through ubiquitination [40,41]. Co-IP analyses further confirmed the interaction between AHSA1 and TRIM8 in aged hearts of CHK1-cKO mice (Supplemental Fig. 16B). Notably, CHK1 overexpression attenuated the AHSA1-TRIM8 interaction, whereas CHK1 knockout strengthened this association, without affecting TRIM8 expression (Fig. 6G–H, Supplemental Fig. 16C–F). AHSA1, the most potent activator of HSP90's ATPase domain, has been shown to interact with HSP90 and augment its ATP hydrolysis activity [37]. To further explore whether CHK1 modulates the interaction between AHSA1 and HSP90, Co-IP experiments were carried out. In cardiomyocytes from young (1-month-old) and aged (24-month-old) mice, the CHK1-AHSA1 interaction was reduced with aging (Supplemental Fig. 17A). Consistently, CHK1 overexpression in senescent cardiomyocytes significantly enhanced the AHSA1-HSP90 interaction, whereas CHK1 knockout largely abolished this effect (Fig. 6I–J). Collectively, these findings identify CHK1 as a key regulator of the AHSA1-HSP90 axis, acting through TRIM8-mediated ubiquitination to maintain proteostasis during cardiac aging. CHK1 activates AHSA1/HSP90-mediated mitophagy to attenuate cardiac aging in mice To further investigate the role of AHSA1 in cardiac aging, we conducted Western blot and qRT-PCR analyses, which revealed an age-dependent decline in both AHSA1 protein and mRNA levels (Supplemental Fig. 18A–B). To investigate the effect of AHSA1 on cardiac aging, 24-month-old WT mice were intravenously injected with AAV9-cTNT-AHSA1 or AAV9-cTNT-vector (Supplemental Fig. 19A). Subsequent Western blot analysis confirmed the effective transfection of AHSA1, showing that while the HSP90 protein level remained unchanged, AHSA1 overexpression markedly enhanced HSP90 ATPase activity (Supplemental Fig. 19B–C). Concomitantly, AHSA1 overexpression robustly activated PINK1/Parkin-mediated mitophagy, leading to reduced accumulation of ROS and DNA damage in the myocardium of aged mice (Supplemental Fig. 19D–F). Moreover, AHSA1 overexpression markedly attenuated cardiomyocyte apoptosis in aged mice (Supplemental Fig. 19G). Further analyses revealed that AHSA1 overexpression markedly diminished the expression levels of SASP (IL-1β and IL-6) and aged markers (p21 and p16INK4A), decreased cardiomyocyte cross-sectional area, alleviated cardiomyocytes hypertrophy, improved cardiac function, and reduced fibrotic scar size in aged mice (Supplemental Fig. 19H–M). These results collectively suggest that AHSA1 mitigates cardiac aging by enhancing HSP90-mediated mitophagy in senescent cardiomyocytes. Following this, we further examined whether cardiomyocyte-specific AHSA1 knockdown in aged mice compromises CHK1-mediated restoration of cardiomyocyte mitophagy and the subsequent attenuation of cardiac aging (Fig. 7A). In aged mouse hearts, AHSA1 knockdown profoundly reduced HSP90 ATPase activity, an effect partially rescued by CHK1 overexpression, while not affecting HSP90 protein expression (Fig. 7B–C). Further analyses revealed that AHSA1 knockdown markedly suppressed PINK1/Parkin-mediated mitophagy, as evidenced by decreased PINK1, Parkin, and LC3-II levels, along with increased p62 accumulation, whereas these changes were largely reversed by CHK1 overexpression (Fig. 7D, Supplemental Fig. 20A). Moreover, AHSA1 knockdown provoked excessive ROS accumulation, aggravated DNA damage, and heightened cardiomyocyte apoptosis, all of which were strikingly reversed upon CHK1 overexpression (Fig. 7E–F, Supplemental Fig. 21A). Furthermore, AHSA1 knockdown in aged mouse hearts substantially upregulated the expression levels of SASP (IL-1β and IL-6) and aged markers (p21 and p16INK4A), whereas CHK1 overexpression partially counteracted these alterations (Fig. 7G–H). Additionally, AHSA1 knockdown resulted in marked cardiomyocyte hypertrophy, impaired cardiac function, and increased fibrotic scar size, effects that were partially alleviated by CHK1 overexpression (Fig. 7I–K). These findings delineate AHSA1 as a pivotal downstream effector of CHK1, essential for maintaining PINK1/Parkin-mediated mitophagy in senescent cardiomyocytes and mitigating cardiac aging.Fig. 7AHSA1 knockdown diminishes the protective effects of CHK1 on mitophagy and cardiac aging in aging mice. A, Schematic diagram. 24-month-old WT and CHK1-TG mice were injected with adeno-associated virus 9 (AAV9) encoding either cTNT-vectori or cTNT-AHSA1i. B, Western Blot analysis and quantification of HSP90 and AHSA1 proteins expression in cardiac tissue from each group (n = 6). C, HSP90 ATPase activity was measured in cardiac tissue from each group (n = 6). D, Western Blot analysis and quantification of proteins (p62 and LC3-Ⅱ) expression in cardiac tissue from each group (n = 6). E, Representative immunofluorescent images and quantification of relative fluorescence intensity of DHE staining in cardiac tissue from each group (n = 6). DHE (orange), Hoechst (blue). Scale bar = 50 μm. F, Representative immunofluorescent images and quantification of relative fluorescence intensity of γH2AX staining in cardiac tissue from each group (n = 6). cTNT (red), γH2AX (green), Hoechst (blue). Scale bar = 20 μm. G, Western Blot analysis and quantification of IL-1β and IL-6 proteins expression in cardiac tissue from each group (n = 6). H, Western Blot analysis and quantification of p21 and p16INK4A proteins expression in cardiac tissue from each group (n = 6). I, WGA immunofluorescence staining and quantification analysis of cardiomyocyte size in cardiac tissue from each group (n = 6). WGA (red), Hoechst (blue). Scale bar = 10 μm. J, Quantification of left ventricular EF, FS, LVID; d and LVID; s in each group (n = 6). K, Representative Masson's trichrome staining images and quantification of fibrotic area in cardiac tissue from each group (n = 6). Scale bar = 100 μm. B–K. Statistical analyses were performed by one-way ANOVA followed by Tukey multiple comparisons. AHSA1 knockdown diminishes the protective effects of CHK1 on mitophagy and cardiac aging in aging mice. A, Schematic diagram. 24-month-old WT and CHK1-TG mice were injected with adeno-associated virus 9 (AAV9) encoding either cTNT-vectori or cTNT-AHSA1i. B, Western Blot analysis and quantification of HSP90 and AHSA1 proteins expression in cardiac tissue from each group (n = 6). C, HSP90 ATPase activity was measured in cardiac tissue from each group (n = 6). D, Western Blot analysis and quantification of proteins (p62 and LC3-Ⅱ) expression in cardiac tissue from each group (n = 6). E, Representative immunofluorescent images and quantification of relative fluorescence intensity of DHE staining in cardiac tissue from each group (n = 6). DHE (orange), Hoechst (blue). Scale bar = 50 μm. F, Representative immunofluorescent images and quantification of relative fluorescence intensity of γH2AX staining in cardiac tissue from each group (n = 6). cTNT (red), γH2AX (green), Hoechst (blue). Scale bar = 20 μm. G, Western Blot analysis and quantification of IL-1β and IL-6 proteins expression in cardiac tissue from each group (n = 6). H, Western Blot analysis and quantification of p21 and p16INK4A proteins expression in cardiac tissue from each group (n = 6). I, WGA immunofluorescence staining and quantification analysis of cardiomyocyte size in cardiac tissue from each group (n = 6). WGA (red), Hoechst (blue). Scale bar = 10 μm. J, Quantification of left ventricular EF, FS, LVID; d and LVID; s in each group (n = 6). K, Representative Masson's trichrome staining images and quantification of fibrotic area in cardiac tissue from each group (n = 6). Scale bar = 100 μm. B–K. Statistical analyses were performed by one-way ANOVA followed by Tukey multiple comparisons. CHK1 overexpression significantly attenuates DOX-induced acutely senescence in hiPSC-CMs To investigate the translational potential of CHK1, DOX-induced acutely senescent hiPSC-CMs were transfected with Ad5:cTNT-CHK1 or Ad5:cTNT-vector. The CHK1 overexpression efficiency was validated by qRT-PCR and Western blot (Fig. 8A, Supplemental Fig. 22A). Subsequent investigation of DOX-induced acutely senescent hiPSC-CMs revealed that CHK1 overexpression significantly suppressed the expression levels of SASP (IL-1β and IL-6) (Fig. 8B, Supplemental Fig. 22B), consistent with the findings from in vivo and in vitro mouse models. Furthermore, CHK1 overexpression markedly reduced both mRNA and protein levels of p21 and p16INK4A in DOX-induced acutely senescent hiPSC-CMs (Fig. 8C, Supplemental Fig. 22C). Additionally, CHK1 overexpression effectively mitigated cardiomyocyte hypertrophy in DOX-induced acutely senescent hiPSC-CMs, as evidenced by a significant reduction in mRNA expression levels of ANP and BNP, along with a decrease in cardiomyocyte size (Fig. 8D–E). Meanwhile, CHK1 overexpression alleviated oxidative stress and suppressed apoptosis, reflected by lower ROS levels and a diminished proportion of cardiomyocyte apoptosis (Fig. 8F–G). These findings suggest that CHK1 offers a potential therapeutic approach to attenuate cardiac aging.Fig. 8CHK1 is vital for DOX-induced acutely senescence in hiPSC-CMs. A, Western Blot analysis and quantification of CHK1 protein expression in hiPSC-CMs transfected with Ad5: cTNT-vector or Ad5: cTNT-CHK1 following DOX treatment (n = 6). B, Western Blot analysis and quantification of IL-1β and IL-6 proteins expression in hiPSC-CMs transfected with Ad5: cTNT-vector or Ad5: cTNT-CHK1 following DOX treatment (n = 6). C, Western Blot analysis and quantification of p21 and p16INK4A proteins expression in hiPSC-CMs transfected with Ad5: cTNT-vector or Ad5: cTNT-CHK1 following DOX treatment (n = 6). D, qRT-PCR analysis and quantification of ANP and BNP mRNA expression in hiPSC-CMs transfected with Ad5: cTNT-vector or Ad5: cTNT-CHK1 following DOX treatment (n = 6). E, Representative immunofluorescent images and quantification of cardiomyocyte size in hiPSC-CMs transfected with Ad5: cTNT-vector or Ad5: cTNT-CHK1 following DOX treatment (n = 6). cTNT (green), Hoechst (blue). Scale bar = 20 μm. F, Representative immunofluorescent images and quantification of relative fluorescence intensity of DHE staining in hiPSC-CMs transfected with Ad5: cTNT-vector or Ad5: cTNT-CHK1 following DOX treatment (n = 6). DHE (orange), Hoechst (blue). Scale bar = 50 μm. G, Representative immunofluorescent images and quantification of Tunel positive CMs in hiPSC-CMs transfected with Ad5: cTNT-vector or Ad5: cTNT-CHK1 following DOX treatment (n = 6). cTNT (green), Tunel (red), Hoechst (blue). Scale bar = 20 μm. H, Schematic illustration of how CHK1 regulates AHSA1/HSP90-mediated mitophagy in cardiac aging. A-G. Statistical analyses were performed by unpaired Student t-test. CHK1 is vital for DOX-induced acutely senescence in hiPSC-CMs. A, Western Blot analysis and quantification of CHK1 protein expression in hiPSC-CMs transfected with Ad5: cTNT-vector or Ad5: cTNT-CHK1 following DOX treatment (n = 6). B, Western Blot analysis and quantification of IL-1β and IL-6 proteins expression in hiPSC-CMs transfected with Ad5: cTNT-vector or Ad5: cTNT-CHK1 following DOX treatment (n = 6). C, Western Blot analysis and quantification of p21 and p16INK4A proteins expression in hiPSC-CMs transfected with Ad5: cTNT-vector or Ad5: cTNT-CHK1 following DOX treatment (n = 6). D, qRT-PCR analysis and quantification of ANP and BNP mRNA expression in hiPSC-CMs transfected with Ad5: cTNT-vector or Ad5: cTNT-CHK1 following DOX treatment (n = 6). E, Representative immunofluorescent images and quantification of cardiomyocyte size in hiPSC-CMs transfected with Ad5: cTNT-vector or Ad5: cTNT-CHK1 following DOX treatment (n = 6). cTNT (green), Hoechst (blue). Scale bar = 20 μm. F, Representative immunofluorescent images and quantification of relative fluorescence intensity of DHE staining in hiPSC-CMs transfected with Ad5: cTNT-vector or Ad5: cTNT-CHK1 following DOX treatment (n = 6). DHE (orange), Hoechst (blue). Scale bar = 50 μm. G, Representative immunofluorescent images and quantification of Tunel positive CMs in hiPSC-CMs transfected with Ad5: cTNT-vector or Ad5: cTNT-CHK1 following DOX treatment (n = 6). cTNT (green), Tunel (red), Hoechst (blue). Scale bar = 20 μm. H, Schematic illustration of how CHK1 regulates AHSA1/HSP90-mediated mitophagy in cardiac aging. A-G. Statistical analyses were performed by unpaired Student t-test. Discussion In our study, we observed a significant reduction in CHK1 expression in both in vivo and in vitro aging models. CHK1 overexpression effectively attenuated cardiac aging in mice, while CHK1 knockout accelerated this process. Mechanistically, RNA-seq analysis indicated that CHK1 activates HSP90 ATPase activity, thereby promoting PINK1/Parkin-mediated mitophagy in aged cardiomyocytes. Notably, the amino acid domain 1-265 of CHK1 was essential for direct interaction with AHSA1. This interaction stabilized AHSA1 by inhibiting TRIM8-mediated ubiquitination and proteasomal degradation, enhancing the AHSA1-HSP90 association and consequently stimulating HSP90 ATPase activity. These findings reveal a previously unrecognized role for CHK1 in aged cardiomyocytes and elucidate complex molecular mechanisms underlying cardiac aging (Fig. 8H). In our previous study, CHK1 is delineated as a crucial regulator that drives cardiomyocyte proliferation and promotes heart regeneration post-myocardial infarction [17]. Nevertheless, the functional significance of CHK1 in cardiac aging remains largely unexplored. Our current study revealed a progressive decline in CHK1 expression during cardiac aging in mice, with CHK1 overexpression substantially attenuating pathological remodeling and contractile dysfunction in aged mice. Furthermore, CHK1 overexpression effectively ameliorated senescence in DOX-induced acutely hiPSC-CMs. These results highlight the translational potential of CHK1 as a pivotal target for strategies aimed at delaying or even reversing cardiac aging. Mitochondria in senescent cardiomyocytes display intricate structural and functional anomalies. Quantitative analyses reveal a reduction of approximately 30% in mitochondrial density per unit cytoplasm in senescent cardiomyocytes [42], with around 35% exhibiting marked swelling, and some progressing to giant mitochondria [43,44]. These morphological changes disrupt the spatial arrangement of complex IV within the electron transport chain, thereby impeding efficient energy transduction [15,45,46]. Notably, studies in rats have reported that mitochondrial cristae do not undergo pronounced degeneration with advancing age [47], suggesting the presence of species-specific compensatory mechanisms. Moreover, studies have demonstrated that in senescent cardiomyocytes, the mechanical coupling efficiency between mitochondria and the microtubule network is diminished, resulting in disorganized mitochondrial positioning during myocardial contraction and a lack of synchronization between mitochondrial ATP production and myosin ATPase activity [48]. Consequently, due to mitochondrial dysfunction, senescent cardiomyocytes experience increased ROS production, which not only damage macromolecules such as proteins and lipids, but also disrupts DNA architecture at the epigenetic level, ultimately modulating the expression of aging-associated genes and further accelerating cellular senescence [49]. These mitochondrial alterations collectively contribute to exacerbating cardiac aging by disrupting cellular bioenergetics. Mitophagy, as a pivotal regulatory axis of mitochondrial quality control, exerts a critical influence during aging by facilitating the selective removal of senescent or dysfunctional mitochondria, thereby safeguarding the functional competence of the remaining mitochondrial network [16]. Evidence indicates that oleanolic acid (OA) potentiates mitophagy, simultaneously mitigating mitochondrial swelling, restraining ROS accumulation, and rectifying age-associated cardiac remodeling in senescent cardiomyocytes [50]. This implies that targeted removal of aging-compromised mitochondria could serve as a potent strategy to retard cardiac aging. In our study, we observed that CHK1 overexpression in senescent cardiomyocytes robustly augmented mitophagy, resulting in reduced ROS accumulation, mitigation of ROS-induced DNA damage and apoptosis, improved mitochondrial respiratory efficiency, and normalization of aberrant mitochondrial morphology. However, PINK1 knockdown diminished the protective effects of CHK1 on mitophagy and cardiomyocyte senescence, underscoring the indispensable role of mitophagy in mediating CHK1-driven cardioprotective mechanisms. To further clarify downstream mechanisms through which CHK1 influences mitochondrial quality control, we conducted pathway enrichment analysis and identified significant enrichment for "HSP90 protein binding," suggesting potential involvement of the HSP90 chaperone system in CHK1-mediated mitophagy. HSP90 functions as a central molecular chaperone, maintaining proteostasis via ATPase-driven conformational changes regulated primarily by co-chaperones rather than by expression alterations [[51], [52], [53], [54]]. Accordingly, CHK1 did not influence HSP90 expression at mRNA or protein levels but notably enhanced its ATPase activity, indicating regulation at a functional rather than transcriptional level. Mechanistically, IP-MS analysis identified AHSA1 as an interacting protein with CHK1 in aged hearts. AHSA1, a well-documented co-chaperone, directly increases HSP90 ATPase activity and is essential for adaptive stress responses [53,54]. Previous studies indicated that disruption of the AHSA1-HSP90 complex impaired autophagy and mitochondrial quality control [38,52]. Our results suggest that CHK1 activates HSP90 ATPase activity through AHSA1, thereby promoting PINK1/Parkin-dependent mitophagy and preserving mitochondrial integrity in aged cardiomyocytes. HSP90, an evolutionarily conserved molecular chaperone ubiquitously expressed across eukaryotic cells, plays a pivotal role in various essential cellular processes by dynamically interacting with client proteins, thereby modulating fundamental pathways such as apoptosis and autophagy [30,31]. Previous studies have demonstrated that HSP90 overexpression potentiates mitophagy in chick hepatocytes, protecting against heat-induced cellular injury [55]. In contrast, HSP90 knockdown impairs mitophagy in human osteosarcoma cells, consequently diminishing their responsiveness to cisplatin [56]. AHSA1, the most efficacious activator of HSP90 ATPase domain, directly interacts with HSP90, boosting its ATP hydrolysis activity [37]. Research has shown that TL-2-8 disrupts the formation of the AHSA1-HSP90 complex, which leads to a reduction in HSP90 ATPase activity and impairs its function, thereby inhibiting the processing and folding of LAMP2 and resulting in decreased mitophagy [38]. Our study demonstrated that the 1-265 domain of CHK1 directly binds to AHSA1, inhibiting its ubiquitin-mediated degradation and promoting the assembly of the AHSA1-HSP90 complex, thereby enhancing mitophagy. Remarkably, AHSA1 knockdown completely abolished the effect of CHK1 on maintaining PINK1/Parkin-dependent mitophagy and attenuating cardiac aging, highlighting AHSA1 as a critical mediator of CHK1-driven cardioprotective mechanisms. In this study, CHK1 manipulation was primarily restricted to cardiomyocytes rather than fibroblasts, suggesting indirect antifibrotic effects mediated through cardiomyocyte homeostasis regulation. We propose that CHK1 alleviates cardiac fibrosis by suppressing cardiomyocyte senescence, thereby improving the cardiac microenvironment and limiting fibroblast activation and fibrotic remodeling. Cardiomyocyte senescence is recognized as a key contributor to cardiac fibrosis through the senescence-associated secretory phenotype (SASP), which promotes proinflammatory and profibrotic mediator secretion [10,57]. Consistent with this, CHK1 activation reduces cardiomyocyte senescence and associated SASP-mediated profibrotic signaling, thus limiting fibroblast activation. In addition, CHK1/AHSA1 signaling restores mitophagy in senescent cardiomyocytes. Because mitochondrial dysfunction and increased ROS production drive both cellular senescence and profibrotic signaling, enhancing mitochondrial quality control, particularly via PINK1/Parkin-mediated mitophagy, alleviates stress-related pathways and ultimately decreases extracellular matrix deposition [[58], [59], [60]]. Furthermore, CHK1 activation mitigates cardiomyocyte apoptosis and cellular stress, thus reducing the release of damage-associated signals that stimulate paracrine fibroblast activation. Maintaining cardiomyocyte integrity further supports a non-profibrotic cardiac microenvironment. Finally, through AHSA1-dependent regulation of HSP90 chaperone activity, CHK1 preserves cardiomyocyte proteostasis, reducing proteotoxic stress and preventing maladaptive remodeling linked to aging and fibrosis. Collectively, these findings highlight CHK1's role in attenuating cardiac fibrosis via coordinated regulation of cardiomyocyte senescence, mitochondrial function, apoptosis, and proteostasis. These cardiomyocyte-intrinsic effects collectively reshape the cardiac microenvironment, ultimately suppressing fibroblast activation and fibrotic remodeling. In the present study, our findings indicate that the cardioprotective effects of CHK1 primarily arise from its regulation of mitochondrial quality control via the AHSA1-HSP90 signaling axis. Thus, the beneficial outcomes associated with CHK1 activation in cardiac tissue appear largely mediated by downstream chaperone-dependent processes rather than direct, global modulation of CHK1 itself. Consequently, targeting specific downstream effectors or functional nodes within the CHK1 signaling pathway may enhance tissue specificity and potentially improve safety compared to direct CHK1 inhibition. From a translational viewpoint, dysregulated mitochondrial quality control and impaired proteostasis are central features of ischemic heart disease and cardiac aging [11,61,62]. Modulation of the CHK1-AHSA1-HSP90 axis therefore presents a potential therapeutic approach to restore mitophagy and enhance cardiac resilience under stress. This strategy is particularly appealing, as it refocuses therapeutic intervention from a broadly essential kinase to a more disease-relevant chaperone-mediated mitochondrial regulatory module. However, the systemic implications, long-term safety, and tissue-specific effects of CHK1 pathway modulation remain incompletely understood, necessitating further preclinical studies to define therapeutic windows, off-target risks, and clinical feasibility. From a translational standpoint, impaired mitochondrial quality control and defective mitophagy characterize cardiac aging and significantly contribute to age-related cardiovascular disorders such as heart failure, ischemic cardiomyopathy, and other cardiac dysfunctions [61,63,64]. Mitochondrial dysfunction correlates closely with cardiomyocyte loss, elevated oxidative stress, and progressive cardiac performance decline in elderly individuals, underscoring mitochondrial homeostasis as a promising therapeutic target [[65], [66], [67]]. Although HSP90 is extensively studied in cancer and neurodegenerative diseases as a critical regulator of proteostasis, its role in cardiovascular aging remains relatively unexplored [[68], [69], [70], [71]]. By elucidating the CHK1-AHSA1-HSP90 axis as a regulatory mechanism for mitophagy, our study provides new insights into maintaining mitochondrial quality control in aging hearts. This highlights the potential therapeutic utility of targeting this pathway. Modulation of CHK1 activity or stabilization of the AHSA1/HSP90 complex might enhance mitophagy, mitigate mitochondrial dysfunction, and ultimately improve cardiac function in aging populations. Our findings thus advance the understanding of cardiac aging mechanisms and identify a promising translational target for age-related CVD interventions. The findings of this study underscore several key points: (1) CHK1 expression progressively declines in both in vivo and in vitro models of cardiac aging, while CHK1 overexpression markedly attenuates cardiac aging in aged mice, suggesting CHK1 as a pivotal therapeutic modality to delay or reverse cardiac aging; (2) CHK1 initiates PINK1/Parkin-mediated mitophagy through activation of HSP90 ATPase activity in aged mice; (3) AHSA1 acts as a direct downstream effector of CHK1, with the 1-265 amino acid domain of CHK1 binding to AHSA1 to suppress TRIM8-mediated ubiquitin-dependent degradation of AHSA1, thereby promoting its interaction with HSP90. Nevertheless, this study is accompanied by several limitations: (1) While our results demonstrate that CHK1 overexpression stimulates HSP90-mediated mitophagy, the precise mechanistic pathways through which HSP90 regulates this process remain largely unresolved; (2) Our study did not comprehensively evaluate in vivo mitophagy. While increased expression of PINK1 and Parkin, as well as enhanced colocalization of PINK1 with Tomm20, suggest activation of the mitophagic pathway, these observations do not definitively confirm mitophagic flux. More conclusive evidence would require assessing Parkin translocation or employing mitophagy-specific reporter systems. Future research should address these aspects to fully substantiate the role of CHK1 in regulating mitophagy in vivo; (3) Although our study demonstrated the involvement of CHK1 in both DOX-induced acutely senescence and physiological cardiac aging, several limitations should be acknowledged. Due to the relatively low yield, reduced viability, and limited transfection efficiency of primary cardiomyocytes isolated from aged mice, extensive mechanistic studies in aged cardiomyocytes were technically challenging in the current study. Therefore, additional functional and mechanistic validation using aged primary cardiomyocytes should be explored in future investigations. In summary, our study reveals a previously unrecognized role of the CHK1/AHSA1/HSP90 axis in promoting mitophagy and attenuating cardiac aging in mice, highlighting the potential of CHK1 modulation as a novel therapeutic approach for delaying cardiac aging. CRediT authorship contribution statement Peng Jing: Conceptualization, Data curation, Formal analysis, Investigation, Methodology, Resources, Software, Validation, Visualization, Writing – original draft. Liu-Hua Zhou: Conceptualization, Data curation, Methodology, Software, Validation, Writing – original draft. Shu-Xuan Chen: Methodology, Software, Visualization. Jia-Yi Chen: Methodology, Software, Validation. Ling-Feng Gu: Software, Validation. Tong-Tong Yang: Validation. Si-Bo Wang: Software. Chong Du: Software. Yi-Xi Chen: Software. Qi-Ming Wang: Data curation, Supervision. Lian-Sheng Wang: Data curation, Funding acquisition, Project administration, Supervision. Hao Wang: Data curation, Funding acquisition, Project administration, Supervision, Writing – review & editing. Declaration of competing interest The authors declare no competing interests.